US Bancorp’s Immunomedics Inc IMMU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-7,344
Closed -$624K 3964
2020
Q3
$624K Sell
7,344
-3,222
-30% -$163K ﹤0.01% 1214
2020
Q2
$375K Buy
10,566
+908
+9% +$26.5K ﹤0.01% 1453
2020
Q1
$130K Buy
9,658
+302
+3% +$5.08K ﹤0.01% 1894
2019
Q4
$198K Buy
9,356
+2,607
+39% +$46K ﹤0.01% 1829
2019
Q3
$90K Hold
6,749
﹤0.01% 2215
2019
Q2
$94K Buy
6,749
+2,423
+56% +$36.5K ﹤0.01% 2251
2019
Q1
$83K Buy
4,326
+4,126
+2,063% +$66.5K ﹤0.01% 2283
2018
Q4
$3K Hold
200
﹤0.01% 3370
2018
Q3
$4K Hold
200
﹤0.01% 3392
2018
Q2
$5K Buy
+200
New +$4.02K ﹤0.01% 3341
2017
Q2
Sell
-2,000
Closed -$13K 3650
2017
Q1
$13K Buy
+2,000
New +$10.1K ﹤0.01% 2980

US Bancorp's IMMU Position: Q4 2020 in Review

US Bancorp sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 7,344 shares — an estimated $624K sold.

US Bancorp first reported a position in IMMU in Q1 2017 and held it in 11 quarters. The position peaked at $624K in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • US Bancorp reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • US Bancorp sold 7,344 Immunomedics Inc shares in Q4 2020, an estimated $624K.
  • US Bancorp first reported a position in Immunomedics Inc in Q1 2017 and held it in 11 quarters.
  • US Bancorp's Immunomedics Inc position peaked at $624K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on US Bancorp's 13F filing for Q4 2020, filed 4 Feb 2021.